Viralym-A

About Adenovirus (AdV)

  • AdV infection in HSCT recipients can manifest itself as pneumonia, hemorrhagic cystitis, nephritis, colitis, hepatitis, and encephalitis, and can even lead to death.
  • Currently there are no FDA approved drugs to treat AdV infection and disease.

Viralym-A

Viralym-A (virus-specific lymphocytes against AdV) is a “ready to administer” T cell immunotherapy product made up of a generated bank of third-party, partially HLA-matched AdV-directed T cells that have been activated from exposure to AdV. We are currently conducting a Phase 1 clinical trial of Viralym-A at The Houston Methodist Hospital and Texas Children’s Hospital in Houston, TX. To learn more, please visit ClincialTrials.gov: NCT02276820

ClincialTrials.gov: NCT02276820